Halozyme Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Halozyme Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Halozyme Therapeutics Inc Strategy Report
- Understand Halozyme Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Halozyme Therapeutics Inc (Halozyme) is a biopharmaceutical company that develops and markets novel recombinant human enzymes for enhancing biologics and drug delivery. Its proprietary technology platform, Enhanze, marketed product, Hylenex recombinant, and focus on R&D are its strengths, even as a decline in licensing fee revenue could be a cause for concern to the company. Halozyme could benefit from strategic initiatives, growing incidence of cancer, and acquisition of Antares Pharma Inc. However, dependence on third-party manufacturers, stringent government regulations and intense competition could affect the company's business.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer